Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Myeloproliferative Disorders 2Anemia, Refractory, with Excess of Blasts 2Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Cytopenia 1

Interventions

Cyclophosphamide 22fludarabine phosphate 18Busulfan 16Antilymphocyte Serum 15Radiotherapy 12Cyclosporine 11Cord Blood Stem Cell Transplantation 11Peripheral Blood Stem Cell Transplantation 10Melphalan 10Filgrastim 10Tacrolimus 9Mycophenolic Acid 9Methylprednisolone 9Methotrexate 9Etoposide 7Cytarabine 7Whole-Body Irradiation 6sargramostim 4Tretinoin 3Thalidomide 3Carboplatin 3venetoclax 2ruxolitinib 2Thiotepa 2Thioguanine 2Specimen Handling 2Sirolimus 2Rituximab 2Leucovorin 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × decitabine and cedazuridine drug combination × Classical hematology × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡